Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The responses of plasma adrenocorticotrophin (ACTH), cortisol, growth hormone (GH) and prolactin to
insulin
-induced hypoglycaemia were studied in six lean male subjects (age 22-29 years). Intravenous
insulin
tests were performed with and without
oxytocin
infusion. Blood sugar nadir occurred at the onset of symptoms (time S) with no significant differences between
oxytocin
and saline infusion. During the
oxytocin
infusion mean plasma
oxytocin
increased from 1.9 pmol/l to 138 pmol/l. Peak increase in plasma ACTH (
oxytocin
266 +/- 54 ng/l; saline 281 +/- 43 ng/l, mean +/- SEM) was at S + 10 min while peak plasma cortisol (
oxytocin
680 +/- 47 nmol/l: saline 656 +/- 40 nmol/l) was measured at S +/- 60 min, peak GH (
oxytocin
96 +/- 17.8 mU/l; saline 106 +/- 18.6 mU/l) at S + 60 min and prolactin (
oxytocin
1332 +/- 239 mU/l; saline 1242 +/- 273 mU/l) at S + 30 min. There were no significant differences in plasma concentrations of ACTH, cortisol, GH or prolactin between saline and
oxytocin
infusion. The results indicate that
oxytocin
has no effect on plasma ACTH, cortisol, GH and prolactin responses to
insulin
-induced hypoglycaemia. In particular they fail to support previous studies which suggested an inhibitory role for
oxytocin
in ACTH secretion.
...
PMID:The effect of oxytocin infusion on adenohypophysial and adrenal cortical responses to insulin-induced hypoglycaemia. 285 20
Injections and infusions of
oxytocin
into conscious dogs caused an increase in plasma concentrations of glucose,
insulin
and glucagon. When blood glucose was clamped at a raised level the injection of
oxytocin
still increased
insulin
and glucagon concentrations in plasma. Infusion of somatostatin suppressed plasma concentrations of glucagon and
insulin
but did not prevent
oxytocin
-induced increments in blood glucose. Injection of
oxytocin
still caused a marked release of glucagon, whereas the
insulin
response was greatly diminished. When endogenous
insulin
and glucagon secretion was suppressed by infusion of somatostatin and glucose levels were stabilized by concomitant infusions of glucagon and
insulin
, injections of
oxytocin
did not alter blood glucose concentrations. It is concluded that the increase in blood glucose following the administration of
oxytocin
is secondary to the release of glucagon and that
oxytocin
exerts a direct stimulatory effect on glucagon and possibly
insulin
secretion.
...
PMID:The mechanism of the effect of oxytocin on plasma concentrations of glucose, insulin and glucagon in conscious dogs. 286 96
The present study investigated the possible effect of somatostatin and
oxytocin
on the basal and stress-induced rise of beta-endorphin (beta-END), beta-lipotrophin (beta-LPH) and cortisol in the human. For this purpose somatostatin (4.1 micrograms/min for 120 min or
oxytocin
(0.4 micrograms/min for 120 min) was infused into two different groups of seven healthy subjects; 30 min after the start of the infusion, placebo or
insulin
(0.1 IU/kg body weight, B.W.) was injected on two different days. In a third experimental step, an
insulin
tolerance test was performed during saline infusion to evaluate stress-related effects on the different hormonal secretions under basal conditions. Plasma levels of beta-END, beta-LPH and cortisol were measured by radioimmunoassay. Extraction and chromatographic procedures preceded the assay for beta-END and beta-LPH. Neither somatostatin nor
oxytocin
significantly modified basal plasma levels of beta-END, beta-LPH and cortisol. However these treatments blunted the rise of the three hormones seen at 45 and 60 min during
insulin
-induced hypoglycaemia (P less than 0.01). These results indicate that somatostatin and
oxytocin
may influence the beta-END, beta-LPH and cortisol increase induced by stress in humans, without affecting their basal secretion.
...
PMID:Somatostatin and oxytocin infusion inhibits the rise of plasma beta-endorphin, beta-lipotrophin and cortisol induced by insulin hypoglycaemia. 287 46
The plasma concentrations of the gastrointestinal regulatory peptides vasoactive intestinal polypeptide (VIP),
insulin
, secretin, somatostatin, motilin, pancreatic polypeptide (PP) and gastric inhibitory polypeptide (GIP), as well as blood glucose, were measured in eight healthy women before, during and after
oxytocin
infusion in post-term pregnancies. Plasma VIP increased significantly (P less than 0.01) during
oxytocin
infusion. Plasma secretin showed a significant (P less than 0.05) decrease during
oxytocin
infusion. Plasma somatostatin remained unchanged during
oxytocin
infusion, but thereafter a significant (P less than 0.05) increase occurred. Both plasma motilin and plasma PP showed a non-significant increase during
oxytocin
infusion with sustained levels thereafter. No changes were found for plasma
insulin
, GIP and blood glucose.
...
PMID:Gastrointestinal regulatory peptides during oxytocin infusion in post-term pregnancies. 290 9
The changes in blood glucose, plasma
oxytocin
, plasma vasopressin, plasma atrial natriuretic peptide, serum osmolality, haematocrit and blood pressure were measured in response to acute
insulin
-induced hypoglycaemia in six normal male subjects. After the i.v. administration of
insulin
(0.15 U/kg), plasma concentrations of
oxytocin
and vasopressin increased rapidly in all subjects and were maximal 15 min after the acute hypoglycaemic reaction (R). Haematocrit increased at the time of the hypoglycaemic reaction, but there was no change in serum osmolality. Systolic blood pressure rose and diastolic blood pressure fell, but mean arterial blood pressure remained unchanged. No changes were demonstrated in plasma concentrations of atrial natriuretic peptide. The release of
oxytocin
and vasopressin in response to acute hypoglycaemia in man is probably caused by stimulation of the posterior pituitary gland via hypothalamic activation, and not by stimulation of osmoreceptors or baroreceptors.
...
PMID:Plasma oxytocin, arginine vasopressin and atrial natriuretic peptide responses to insulin-induced hypoglycaemia in man. 295 4
The hypophysiotropic coding of ACTH secretion resulting from
insulin
-induced hypoglycemia was investigated in urethane-anesthetized fasted rats. The participation of corticotropin-releasing factor (CRF), arginine vasopressin (AVP), and catecholamines in the ACTH response was first investigated by systemic administration of CRF antiserum, an AVP pressor antagonist, or a ganglionic blocking agent. These treatments were without effect on the hypoglycemic response, which was characterized by a 67% fall in systemic glucose levels within 30 min of
insulin
administration. ACTH secretion in response to
insulin
-induced hypoglycemia was differentially affected by these pharmacological treatments. Administration of antiserum to CRF abolished the ACTH response, whereas ganglionic blockade was without significant effect. However, administration of a vasopressinergic pressor antagonist significantly attenuated ACTH secretion after
insulin
treatment. These observations suggested the participation of both CRF and AVP in mediation of the ACTH secretory response to hypoglycemia. Infusion of glucose to counter the hypoglycemia action of
insulin
injection prevented the ACTH secretory response. Measurement of immunoreactive (ir) CRF, irAVP, and ir-
oxytocin
in sequential collections of hypophysial portal plasma revealed a significant elevation of irAVP concentration without concomitant elevation of irCRF or ir-
oxytocin
levels. We propose that CRF functions in a permissive role, maintaining a relatively constant portal concentration and thereby allowing expression of the weaker ACTH-releasing activity of AVP and other secretagogues. Thus, AVP, not CRF, appears to represent the dynamic mediator of ACTH secretion accompanying
insulin
-induced hypoglycemia. These observations provide additional support for the hypothesis of multifactor stimulus-specific hypophysiotropic coding of ACTH secretion.
...
PMID:Hypophysiotropic regulation of adrenocorticotropin secretion in response to insulin-induced hypoglycemia. 298 21
The neuropeptides arginine vasopressin and
oxytocin
are generated from their prohormones in the hypothalamoneurohypophysial system by enzymatic cleavages at paired basic residues (i.e. Lys-Arg). This study describes the purification of an enzyme from bovine neural lobe secretory vesicles, the putative site of this processing, which is capable of cleaving several prohormones at paired basic residues. The enzyme is a glycoprotein of Mr approximately 70,000 and has an acidic pH maximum. It processes the heterologous precursors pro-opiomelanocortin and
insulin
at paired basic residues in a manner similar to a pro-opiomelanocortin-converting enzyme derived from bovine intermediate lobe secretory vesicles which has been described previously. In addition, the neural lobe-derived converting enzyme cleaves the human vasopressin prohormone in vitro to yield arginine vasopressin-Gly10-Lys11-Arg12 as the major vasopressin cleavage product. This indicates that the enzymatic cleavage in the vasopressin precursor occurred primarily on the carboxyl side of the arginine in the pair of Lys-Arg basic residues separating the vasopressin peptide from the
neurophysin
moiety in the precursor. The properties of the neural and intermediate lobe-derived enzymes are virtually identical, raising the possibility that a family of similar enzymes may be responsible for cleaving a number of prohormones at paired basic residues in different tissues.
...
PMID:Purification and characterization of a paired basic residue-specific prohormone-converting enzyme from bovine pituitary neural lobe secretory vesicles. 302 39
ACTH, isoprenaline, forskolin, and dibutyryl cyclic AMP prevented
insulin
from stimulating adipocyte pyruvate dehydrogenase in the presence of adenosine deaminase. Antagonism was reversed by N6-phenylisopropyladenosine as well as
oxytocin
. The stimulatory effects of
insulin
, adenosine and
oxytocin
on adipocyte pyruvate dehydrogenase appear to be through (a) mechanism(s) which is (are) similar or related.
...
PMID:Adenosine and oxytocin reverse antagonism of cyclic AMP elevating agents to insulin activation of adipocyte pyruvate dehydrogenase. 303 Aug 21
Treatment of isolated rat adipocytes with epinephrine or isoproterenol caused a time- and concentration-dependent increase in phospholipid methyltransferase (PLMT) activity that was blocked by propranolol and unaffected by phentolamine. Forskolin mimicked the stimulatory effect on PLMT, and
insulin
inhibited this effect. In both the absence and presence of
insulin
, there was a linear relationship between PLMT activity and lipolysis. PLMT activity was also increased in response to
oxytocin
, which does not activate adenylate cyclase in adipocytes and does not stimulate lipolysis. The effects of
oxytocin
were inhibited by
insulin
and were additive with those of isoproterenol on PLMT. These data support the hypothesis that in adipocytes, PLMT is activated by a cAMP-dependent protein kinase and a cAMP-independent mechanism, both of which can be regulated independently, and both of which are sensitive to inhibition by
insulin
.
...
PMID:Hormonal regulation of phospholipid methyltransferase by 3',5'-cyclic adenosine monophosphate-dependent and independent mechanisms. 303 90
In previous in Vitro and in Vivo studies
oxytocin
was shown to stimulate A and B cell secretion. In the present study we show that
oxytocin
is also able to increase arginine-induced glucagon and
insulin
secretion in healthy human beings. Similar results were obtained in both
insulin
-dependent (type-1) and non-
insulin
dependent (type-2) diabetic subjects.
...
PMID:Oxytocin increases arginine-induced A and B cell secretion in normal man and in diabetic subjects. 304 83
<< Previous
1
2
3
4
5
6
7
8
9
10